OTCM
CPMV
Market cap2mUSD
Jul 09, Last price
0.41USD
1D
-16.96%
1Q
-35.41%
Jan 2017
10,025.00%
Name
Mosaic Immunoengineering Inc
Chart & Performance
Profile
Mosaic ImmunoEngineering Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. It offers MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in mice, dogs, and humans. The company was founded in 2020 and is based in Novato, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|
2022‑12 | 2021‑12 | 2020‑12 | 2020‑05 | 2018‑05 | 2017‑05 | 2016‑05 | |
Income | |||||||
Revenues | |||||||
Cost of revenue | 2,628 | ||||||
Unusual Expense (Income) | |||||||
NOPBT | (2,628) | ||||||
NOPBT Margin | |||||||
Operating Taxes | 2 | ||||||
Tax Rate | |||||||
NOPAT | (2,630) | ||||||
Net income | (2,381) -35.38% | ||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 343 | ||||||
BB yield | -4.79% | ||||||
Debt | |||||||
Debt current | |||||||
Long-term debt | 1,228 | ||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | 1,008 | ||||||
Cash flow | |||||||
Cash from operating activities | (690) | ||||||
CAPEX | |||||||
Cash from investing activities | 343 | ||||||
Cash from financing activities | 342 | ||||||
FCF | (1,037) | ||||||
Balance | |||||||
Cash | 221 | ||||||
Long term investments | |||||||
Excess cash | 221 | ||||||
Stockholders' equity | (6,908) | ||||||
Invested Capital | 3,252 | ||||||
ROIC | |||||||
ROCE | 71.86% | ||||||
EV | |||||||
Common stock shares outstanding | 7,236 | ||||||
Price | 0.99 -2.94% | ||||||
Market cap | 7,163 4.62% | ||||||
EV | 8,171 | ||||||
EBITDA | (2,628) | ||||||
EV/EBITDA | |||||||
Interest | 152 | ||||||
Interest/NOPBT |